Literature DB >> 10195771

Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide.

T L McInerney1, F R Brennan, T D Jones, N J Dimmock.   

Abstract

The ability of five different adjuvants (alum, complete Freund's adjuvant, Quil A, AdjuPrime and Ribi) to stimulate humoral and T-cell mediated immune responses against a purified chimeric virus particle was investigated. Each adjuvant was administered subcutaneously to adult mice together with 10 microg of wildtype (wt) cowpea mosaic virus (CPMV) or a chimeric CPMV displaying the HIV-1 gp41 peptide, residues 731-752. All preparations elicited strong antibody responses to CPMV, but Quil A elicited the highest and most consistent responses to the HIV-1 peptide. This finding was reflected in both ELISA titres with immobilized peptide and in HIV-1-neutralizing antibody. In addition Quil A was also, the only adjuvant to stimulate an in vitro proliferative T-cell response. Surprisingly with all adjuvant formulations a predominately IgG2a anti-gp41 peptide response was observed, indicating a type 1 T-helper cell-like response. Furthermore, the efficiency of the CPMV display system was demonstrated by its ability to induce good levels of peptide specific antibody in the absence of any adjuvant.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195771     DOI: 10.1016/s0264-410x(98)00388-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Therapeutic Chlamydophila abortus and C. pecorum vaccination transiently reduces bovine mastitis associated with Chlamydophila infection.

Authors:  Carolin Biesenkamp-Uhe; Yihang Li; Hans-Robert Hehnen; Konrad Sachse; Bernhard Kaltenboeck
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

2.  Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells.

Authors:  Denis Leclerc; Diane Beauseigle; Jérome Denis; Hélène Morin; Christine Paré; Alain Lamarre; Réjean Lapointe
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

Review 3.  Cowpea mosaic virus as a vaccine carrier of heterologous antigens.

Authors:  F R Brennan; T D Jones; W D Hamilton
Journal:  Mol Biotechnol       Date:  2001-01       Impact factor: 2.695

4.  Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry.

Authors:  Tia Estey; Christina Vessely; Theodore W Randolph; Ian Henderson; Latoya Jones Braun; Rajiv Nayar; John F Carpenter
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

5.  Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I.

Authors:  Angel M Cuesta; Eduardo Suárez; Martin Larsen; Kim Bak Jensen; Laura Sanz; Marta Compte; Peter Kristensen; Luis Alvarez-Vallina
Journal:  Immunology       Date:  2006-04       Impact factor: 7.397

Review 6.  Advancements in protein nanoparticle vaccine platforms to combat infectious disease.

Authors:  Nina Butkovich; Enya Li; Aaron Ramirez; Amanda M Burkhardt; Szu-Wen Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-11-08

Review 7.  Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants.

Authors:  Marie-Ève Lebel; Karine Chartrand; Denis Leclerc; Alain Lamarre
Journal:  Vaccines (Basel)       Date:  2015-08-05

8.  Immunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles.

Authors:  Sarah A Kessans; Mark D Linhart; Lydia R Meador; Jacquelyn Kilbourne; Brenda G Hogue; Petra Fromme; Nobuyuki Matoba; Tsafrir S Mor
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

Review 9.  Plant-based strategies aimed at expressing HIV antigens and neutralizing antibodies at high levels. Nef as a case study.

Authors:  Carla Marusic; Alessandro Vitale; Emanuela Pedrazzini; Marcello Donini; Lorenzo Frigerio; Ralph Bock; Philip J Dix; Matthew S McCabe; Michele Bellucci; Eugenio Benvenuto
Journal:  Transgenic Res       Date:  2009-01-25       Impact factor: 2.788

10.  Chemical addressability of ultraviolet-inactivated viral nanoparticles (VNPs).

Authors:  Chris Rae; Kristopher J Koudelka; Giuseppe Destito; Mayra N Estrada; Maria J Gonzalez; Marianne Manchester
Journal:  PLoS One       Date:  2008-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.